Design Therapeutics Reports on Shareholder Vote Matters
Ticker: DSGN · Form: 8-K · Filed: Jun 12, 2025 · CIK: 1807120
| Field | Detail |
|---|---|
| Company | Design Therapeutics, Inc. (DSGN) |
| Form Type | 8-K |
| Filed Date | Jun 12, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
Design Therapeutics held a shareholder vote on June 10th; details filed today.
AI Summary
Design Therapeutics, Inc. filed an 8-K on June 12, 2025, reporting on matters submitted to a vote of its security holders on June 10, 2025. The filing details the company's corporate actions and governance decisions.
Why It Matters
This filing informs investors about key decisions made by Design Therapeutics' shareholders, which could impact the company's strategic direction and governance.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a shareholder vote and does not indicate any immediate financial or operational risks.
Key Players & Entities
- Design Therapeutics, Inc. (company) — Registrant
- June 10, 2025 (date) — Date of earliest event reported
- June 12, 2025 (date) — Date of report
FAQ
What specific matters were submitted to a vote of Design Therapeutics' security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not enumerated in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on June 10, 2025.
What is the exact name of the registrant?
The exact name of the registrant is Design Therapeutics, Inc.
What is the Commission File Number for Design Therapeutics, Inc.?
The Commission File Number for Design Therapeutics, Inc. is 001-40288.
Where is Design Therapeutics, Inc. headquartered?
Design Therapeutics, Inc. is headquartered at 6005 Hidden Valley Road, Suite 110, Carlsbad, California, 92011.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 12, 2025 regarding Design Therapeutics, Inc. (DSGN).